---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-042062"
form_type: "8-K"
ticker: "AIMD"
cik: "0001014763"
company_name: "Ainos, Inc."
filed_at: "2024-10-22T23:59:59+00:00"
generated_at: "2026-05-30T11:23:23.386963+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Ainos adds exclusive patent rights and co-development of nitrogen-oxygen separation machine with TCNT

## Summary
- Third Addendum to Product Development Agreement adds nitrogen-oxygen separation machine for medical oxygen and wound healing.
- TCNT grants Ainos exclusive sales rights and full patent authorization for the new machine.
- Exclusive patent use fee set at $50,000/month plus 5% sales tax for one year starting October 16, 2024.
- TCNT controls ~62.9% of Ainos voting power as of October 17, 2024.
- Co-development scope expanded to include VELDONA drug pre-processing and manufacturing development.

## SEC filing metadata
- accession: 0001493152-24-042062
- form_type: 8-K
- ticker: AIMD
- cik: 0001014763
- company_name: Ainos, Inc.
- filed_at: 2024-10-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1014763/000149315224042062/0001493152-24-042062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1014763/000149315224042062/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-042062
- JSON: https://secwatch.observer/filing/0001493152-24-042062.json
- Plain text: https://secwatch.observer/filing/0001493152-24-042062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.